FDA ENFORCEMENT POLICY ON UNAPPROVED IVDs "ENCOURAGES" DEVELOPMENT OF CERTIFICATION PROGRAMS FOR PROPER RESEARCH/INVESTIGATIONAL USE
This article was originally published in The Gray Sheet
Executive SummaryIn vitro diagnostics vendors whose products are intended for research or investigational use only are being asked by FDA -- but not required -- to establish certification programs to prevent improper commercialization of the non-approved tests.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.